NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Note
1 – Organization and Description of Business
MediGap
Healthcare Insurance Company, LLC (the “Company”) operates as an insurance agency earning commission revenue by selling bound
insurance policies with all renewal rights to companies. The Company is based in Boca Raton, Florida and was founded in 2017 as a Florida
Limited Liability Company.
COVID-19
There
have been recent outbreaks in several countries, including the United States, of the highly transmissible and pathogenic coronavirus
(“COVID-19”). The outbreak of such Covid-19 resulted in a widespread health crisis that adversely affected general commercial
activity and the economies and financial markets of many countries, including the United States. Although to date, the Company has not
been adversely affected by Covid-19, the measures taken by the governments of countries affected could adversely affect the Company’s
business, financial condition, and results of operations.
Note
2 – Summary of Significant Accounting Policies
Basis
of Presentation
The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (“GAAP”).
Liquidity
As
of December 31, 2021, the Company’s reported cash balance was approximately $334,000, current assets were approximately $726,000,
while current liabilities were approximately $1,590,000. As of December 31, 2021, the Company had a working capital deficit of approximately
$864,000 and Shareholder’s deficit of $855,000. For the year ended December 31, 2021, the Company reported net income of approximately
$188,000 and positive cash flows from operations of $344,000. Management believes the company’s financial position to be reasonable
and sufficient, providing ample liquidity for the foreseeable future.
Use
of Estimates
The
preparation of these financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the
reported amounts in the financial statements and disclosure in the accompanying notes. Actual results may differ from those estimates
and such differences may be material to the financial statements. The more significant estimates and assumptions by management include
among others: accounts receivable realization, operating expense accruals, and revenue recognition.
Cash
Cash
consists of checking accounts.
Accounts
Receivable
Accounts
receivable consists primarily of amounts due to the Company in relation to commissions owed to the Company. The Company assesses the
collectability of all receivables on an ongoing basis by considering its historical credit loss experience, current economic conditions,
and other relevant factors. Based on this analysis, the Company has determined that no allowance for doubtful accounts was necessary
at December 31, 2021 or 2020.
MEDIGAP
HEALTHCARE INSURANCE COMPANY, LLC
NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Property
and Equipment
Property
and equipment are stated at cost. Depreciation is recorded over the shorter of the estimated useful life or the lease term of the applicable
assets using the straight-line method beginning on the date an asset is placed in service. The Company regularly evaluates the estimated
remaining useful lives of the Company’s property and equipment to determine whether events or changes in circumstances warrant
a revision to the remaining period of depreciation. Estimated useful lives of the Company’s Property and Equipment are as follows:
|
| Useful Life (in
years) |
Furniture and equipment | |
7 |
Leasehold improvements | |
Shorter of the useful life or the lease term |
Computer equipment | |
5 |
Income
Taxes
The
Company has elected to be treated as an S corporation for federal and state purposes. As an S corporation, the company is not liable
for federal or state income taxes. Accordingly, no provision for federal and state income taxes have been reflected in the accompanying
combined financial statements although each company is liable for state franchise taxes. Instead, the taxable income or loss of each
company is allocated and taxable to the respective member.
The
Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05, “Accounting for Uncertainty in Income
Taxes” (the “Subtopic”). The Subtopic clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s
financial statements. The Subtopic prescribes a recognition threshold and measurement attitude for the financial statement recognition
and measurement of a tax position taken or expected to be taken in a tax return. The Subtopic provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosure, and transition.
At
December 31, 2021 and 2020, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were
required. The 2017 through 2020 tax years generally remain subject to examination by federal and most state tax authorities.
In
December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”),
which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. ASU 2019-12
is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted this
pronouncement January 1, 2021, which did not have a material effect on the consolidated financial statements.
Revenue
Recognition
The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606 Revenue from Contracts with Customers,
which at its core, recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration
the entity expects to be entitled to in exchange for those goods or services.
The
following outlines the core principles of ASC 606:
Identification
of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract
with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms
related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially
all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the
promised consideration.
MEDIGAP
HEALTHCARE INSURANCE COMPANY, LLC
NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Identification
of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods
or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the
goods or service either on its own or together with other resources that are readily available from third parties or from us, and are
distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises
in the contract.
Determination
of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange
for transferring goods or services to the customer.
Allocation
of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation,
the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations
require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.
Recognition
of revenue when, or as, the Company satisfies a performance obligation. The Company satisfies performance obligations either over
time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation
is satisfied by transferring the promised good or service to the customer.
The
Company earns commission revenue by selling bound insurance policies with all renewal rights to insurance marketing organizations (the
“Customer”). The Customers utilize innovative actuarial models to value and price policies purchased based on future projections.
Customers pay a one-time commission per policy purchased to selling agencies based on a pre-agreed formula outlined in the parties’
contractual agreement. Commission payments are subject to chargeback in the event a policy is cancelled or lapses within 3 months of
a policy’s effective date or until the first three payments are received from the insured party, depending on the Customer Contract.
The
Company identifies a contract when it has a binding agreement to sell issued insurance policies to the Customer.
There
is one performance obligation in Customer contracts, to sell the rights in Company procured issued insurance policies to the Customer.
The performance obligation is satisfied when the rights to an issued policy have been transferred to the Customer.
Transaction
price is stated in a contract and is a set range of commission amounts based on each policy sold. There are two variable components to
consideration received:
|
a) |
Commissions are only earned
once a policy is “Placed”, defined as, an active policy sold to the Customer where the Customer has received the initial
insurance carrier payment with respect to such policy. The Company requires end-user insured parties to pay the initial premium to
the insurance carrier upon issuance of a policy. Insurance carrier in turn pays Customer its initial payment soon thereafter. Thus,
upon sale of an issued policy to Customer, the Company has provided a bound issued policy and ensured first premium payment has been
completed by insured party. This results in virtual assurance that the Customer will receive its initial insurance carrier payment,
and it is more than probable that a significant revenue reversal will not occur. The Company thus considers all policies sold to
the Customer to be Placed for revenue recognition purposes. |
|
b) |
Commission revenue is subject
to chargeback in full if a policy is cancelled or lapses within three months from the policy effective date or if the insured party
does not make the first three payments of the policy. The Company uses historical activity as well as current factors to estimate
the unconstrained variable consideration for recognition per the expected value method. A chargeback reserve liability is credited
for the difference between cash consideration received and variable consideration recognized. At each reporting period, the Company
remeasures the chargeback reserve liability and recognizes any change as an increase or decrease to the then current period revenue.
As of December 31, 2021 and 2020, the chargeback reserve liability was $1,287,461 and $625,482. |
With
one performance obligation, allocation of transaction price is normally not necessary.
MEDIGAP
HEALTHCARE INSURANCE COMPANY, LLC
NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
The
Company recognizes revenue at a point in time when it satisfies its performance obligation and control of an insurance policy transfers
to the Customer. Transfer of control occurs when the Company submits the Policy to the Customer.
Customers
generally pay the Company weekly, and accruals are recorded as necessary at period end.
General
and Administrative
General
and administrative expenses primarily consist of personnel costs for the Company’s administrative functions, professional service
fees, office rent, all employee travel expenses, and other general costs.
Marketing
and Advertising
The
Company’s direct channel expenses primarily consist of costs for e-mail marketing and newspaper advertisements. The Company’s
online advertising channel expense primarily consist of social media ads. Advertising costs for both direct and online channels are expensed
as incurred. Marketing and advertising costs were $2,010,691 and $2,078,035 for the years ended December 31, 2021 and 2020, respectively.
Concentration
of Credit Risk
Cash
The
Company maintains principally all cash balances in various financial institutions which, at times, may exceed the amount insured by the
Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the respective strength
of the financial institutions. The Company has not incurred any losses on these accounts. At December 31, 2021 and 2020, amounts in excess
of insured limits was $78,294 and $130,825, respectively.
Revenue
For
the year ended December 31, 2021 one customer represented 92% of revenue, and for the year ended December 31, 2020, two customers represented
62% and 32% of revenue, respectively. No other customer accounted for more than 10% of the Company’s commission revenues for the
years ended December 31, 2021 and 2020.
Accounts
Receivable
For
the year ended December 31, 2021, two customers accounted for 79% and 21% of accounts receivable, respectively, and for the year ended
December 31, 2020, one customer accounted for 93% of accounts receivable.
Recently
Issued Accounting Pronouncements
From
time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies.
Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have
a material impact on its financial position or results of operations upon adoption.
In
June 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other
instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss”
model that generally will result in the earlier recognition of allowance for losses. In addition, an entity will have to disclose significantly
more information about allowances, credit quality indicators and past due securities. The standard is effective for the Company beginning
July 1, 2020, including interim periods within those annual periods, the Company is currently evaluating the impact this standard will
have on its financial statements.
MEDIGAP
HEALTHCARE INSURANCE COMPANY, LLC
NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
From
time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard
setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the impact of recently issued
standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon
adoption.
Note
3 – Employee Retention Credit Refund Receivable
On
March 11, 2021, President Biden signed the American Rescue Plan Act (“ARPA”). The ARPA includes several provisions, such
as measures that extend and expand the employee retention credit, previously enacted under the CARES Act, through December 31, 2021.
For the year ended December 31, 2021, the Company recorded an employee retention credit of $333,437 as employee retention credit income
on the statements of operations, and $318,962 as an employee retention credit refund receivable on the balance sheets for the amount
not received. The Company has recorded these amounts at December 31, 2021 as management believes collection is probable as the conditions
in order to receive the refund have been met.
Note
4 – Property and Equipment
Property
and equipment at December 31, 2021 and 2020 consisted of the following:
| |
December 31, | | |
December 31, | |
| |
2021 | | |
2020 | |
Furniture and equipment | |
$ | 24,201 | | |
$ | 24,201 | |
Computer equipment | |
| 13,174 | | |
| 13,174 | |
Leasehold improvements | |
| 9,000 | | |
| 9,000 | |
Property and equipment, gross | |
| 46,375 | | |
| 46,375 | |
Less accumulated depreciation | |
| (25,709 | ) | |
| (17,136 | ) |
Property and equipment, net | |
$ | 20,666 | | |
$ | 29,239 | |
Depreciation
expense was $8,573 and $8,130 for the years ended December 31, 2021 and 2020, respectively.
Note
5 – Accounts Payable and Other Accrued Liabilities
Significant
components of accounts payable and other accrued liabilities at December 31, 2021 and 2020 were as follows:
| |
December 31, 2021 | | |
December 31, 2020 | |
| |
| | |
| |
Accounts payable | |
$ | 35,500 | | |
$ | 144,351 | |
Accrued expenses | |
| 77,301 | | |
| 79,270 | |
Accrued credit card payables | |
| 44,465 | | |
| 41,507 | |
| |
$ | 157,266 | | |
$ | 265,128 | |
MEDIGAP
HEALTHCARE INSURANCE COMPANY, LLC
NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Note
6 – PPP Loan Payable
On
April 29, 2020, the Company entered into a loan agreement with Idaho First Bank for a loan of $125,200 pursuant to the Paycheck Protection
Program (the “PPP”) under the CARES Act. This loan was evidenced by a promissory note dated April 29, 2020 and matures two
years from the disbursement date. This loan bore interest at a rate of 1.00% per annum, with the first six months of interest deferred.
Principal and interest were payable monthly commencing seven months after the disbursement date and could be prepaid by the Company at
any time prior to maturity with no prepayment penalties. This loan contained customary events of default relating to, among other things,
payment defaults or breaches of the terms of the loan. Upon the occurrence of an event of default, the lender may require immediate repayment
of all amounts outstanding under the note. Payments must be paid on the 1st day of each month.
Under
the terms of the PPP, up to the entire amount of principal and accrued interest may be forgiven to the extent loan proceeds are used
for qualifying expenses as described in the CARES Act and applicable implementing guidance issued by the U.S. Small Business Administration
(“SBA”) under the PPP. The Company has used the entire loan amount for designated qualifying expenses, and on April 30, 2021,
the loan balance and accrued interest outstanding were forgiven in full.
On
February 2, 2021, the Company entered into a loan agreement with Idaho First Bank for a second loan of $125,200 pursuant to the Paycheck
Protection Program (the “PPP”) under the CARES Act. This loan is evidenced by a promissory note dated February 2, 2021 and
matures two years from the disbursement date. This loan bears interest at a rate of 1.00% per annum, with the first six months of interest
deferred. Principal and interest are payable monthly commencing seven months after the disbursement date and may be prepaid by the Company
at any time prior to maturity with no prepayment penalties. This loan contains customary events of default relating to, among other things,
payment defaults or breaches of the terms of the loan. Upon the occurrence of an event of default, the lender may require immediate repayment
of all amounts outstanding under the note. Payments must be paid on the 1st day of each month. As of December 31, 2021, the Company has
repaid a total of $0 on this loan.
Note
7 – Leases
Operating
lease
ASU
2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated
over the lease term, generally on a straight-line basis. The standard requires a lessee to record a right-of-use asset and a corresponding
lease liability at the inception of the lease, initially measured at the present value of the lease payments. The Company’s lease
consists of an operating lease on office space with a related party, Rotelli Pizza and Pasta, Inc. From September 1, 2020 through December
31, 2021 the Company subleased a portion of the office space to a related party of the Company.
Lease
expense, net of sublease income, for the years ended December 31, 2021 and 2020 was $133,158 and $152,996, respectively.
In
accordance with ASU 2016-02, right-of-use assets are amortized over the life of the underlying lease. As of December 31, 2021 and 2020,
the Company reflected a right of use asset of $307,041 and $454,681, respectively.
As
of December 31, 2021, the weighted average remaining lease term for the operating leases is 2.00 years. The Company has adopted the practical
expedient under FASB ASC 842-10-65-6 “Leases” and uses a published risk-free rate as the discount rate. The weighted average
discount rate for the operating lease is 2.82%.
MEDIGAP
HEALTHCARE INSURANCE COMPANY, LLC
NOTES
TO FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Future
minimum lease payment under the operating lease consisted of the following:
Future Minimum Lease Payments | |
| |
2022 | |
$ | 166,222 | |
2023 | |
| 182,843 | |
Total undiscounted lease payments | |
| 349,065 | |
Less: imputed interest | |
| (10,276 | ) |
Present value of lease payable | |
$ | 338,789 | |
NOTE
8 – COMMITMENTS AND CONTINGENCIES
Legal
Contingencies
The
Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business.
While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters
will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal
contingencies are accrued as of December 31, 2021 and 2020. Litigation relating to the insurance brokerage industry is not uncommon.
As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or
outcome of any such litigation in the future.
NOTE
9 – RELATED PARTIES
During
2021 and 2020, related parties, family members of the Sole Shareholder, Joseph Billoti, received compensation in the amount of $415,580
and $292,557, respectively.
In
2018, the Company entered into a related party lease agreement with an entity owned by a family member of the Sole Shareholder, incurring
$151,352 and $150,000 of rent expense in 2021 and 2020, respectively, and additionally, the entity received $32,4200 and $31,750 of compensation
in 2021 and 2020, respectively, for bookkeeping services.
During
2021 and 2020, related parties, entities owned by COO, Kyle Perine, received compensation in the amount of $188,700 and $169,200, respectively.
Additionally, an entity owned by the COO received commissions of $40,192 and $0, respectively, for the years ended December 31, 2021
and 2020.
During
2021 and 2020, the Company received recorded cash receipts of revenues belonging to T65 Solutions, an entity owned by an executive employee
of the Company. As of December 31, 2021, no amounts were owed to or from the affiliate. As of December 31, 2021 and 2020, the Company
had amounts receivable from T65 Solutions of $0 and $62,027, respectively.
NOTE
10 – SUBSEQUENT EVENTS
The
Company has completed an evaluation of all subsequent events through March 10, 2022 the date the financial statements were available
to be issued, to ensure that this report includes appropriate disclosure of events both recognized in the December 31, 2021 financial
statements and events which have occurred but were not recognized in the financial statements. The Company has concluded that no subsequent
event has occurred that requires disclosure.
On
January 10, 2022, the Company entered into an agreement with Reliance Global Group, Inc. (“RGG”) pursuant to which RGG purchased
all of the assets of the Company for a purchase price in the amount of $20,096,250 consisting of payments of $18,138,750 in cash and
issuances of 606,037 shares of RGG’s restricted common stock.
APPENDIX
B
UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
On
January 10, 2022, Reliance Global Group, Inc. (the “Company”) entered into an agreement (the “APA”) with Medigap
Healthcare Insurance Company, LLC (“Medigap”) pursuant to which the Company purchased all of the assets of Medigap for a
purchase price in the amount of $22,902,201 consisting to payment to Seller of (i) $18,138,750 in cash and (ii) issuing to Seller 606,037
shares of Buyer’s restricted common stock in a transaction exempt from registration under Section 4(a)(2) of the Securities Act
of 1933, as amended. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities
of the parties. The shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50%
of those shares may be sold after the one year anniversary of the date of Closing the APA and the balance of the shares after the second
year anniversary of the date of closing under the APA.
Also
at the closing, the Company also entered into an employment agreement (“Employment Agreement”) with Kyle Perrin, formerly
Medigap’s chief operating officer, for him to manage the acquired assets. Pursuant to the Employment Agreement, which has a three
year term, Mr. Perrin is paid an annual salary of $200,000 with a one-time bonus of $100,000 within 30 days of the January 10, 2021 closing
and is entitled to an annual bonus of 3.5% of EBITDA of the Company. He is also entitled to then offered Company benefits. He is the
subject of a two year non-compete provision and standard industry termination for cause and good reason provisions apply.
The accompanying unaudited pro forma condensed combined
financial statements (“unaudited pro forma financial information”) has been prepared based on the historical financial statements
of the Company and Medigap after giving effect to the purchase agreement to acquire Medigap. The pro forma financial information is intended
to provide information about how the acquisition of Medigap has affected the Company’s historical consolidated financial statements.
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2021 combines the historical consolidated
statement of operations of the Company for the period, derived from the Company’s December 31, 2021 consolidated financial statements,
with the respective historical statement of operations of Medigap as if the acquisition of Medigap had occurred on January 1, 2021. The
unaudited pro forma condensed combined balance sheet at December 31 ,2021 combines the historical consolidated balance sheet of the Company
as derived from the Company’s December 31, 2021 consolidated financial statements, and the historical balance sheet of Medigap as
of December 31, 2021 on a pro forma basis as if the acquisition of medigap occurred on the same balance sheet date.
The
unaudited pro forma financial information should be read in conjunction with the accompanying notes to the unaudited pro forma financial
information and:
|
● |
The
historical consolidated financial statements of the Company for the year ended December 31, 2021; |
|
|
|
|
● |
the
historical financial statements of Medigap for the year ended December 31, 2021 as included in this Current Report on Form 8-K/A. |
|
|
|
|
● |
the
announcement of the entry into and closing of the Asset Purchase Agreement with Medigap as included in the Current Report on Form
8-K filed with the SEC on January 14, 2022. |
The
unaudited pro forma financial information has been presented for illustrative purposes only and do not necessarily reflect what the combined
company’s financial condition or results of operations would have been had the acquisition of Medigap occurred on the dates indicated.
Further, the unaudited pro forma financial information also may not be useful in predicting the future financial condition and results
of operations of the combined company. The actual financial position and results of operations may differ significantly from the pro
forma amounts reflected herein due to a variety of factors. The unaudited pro forma transaction accounting adjustments represent management’s
estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are
subject to change as additional information becomes available and analyses are performed.
Reliance
Global Group, Inc.
Pro
Forma Condensed Combined Balance Sheet
December
31, 2021
(Unaudited)
| |
Historical | | |
Pro Forma | |
| |
Reliance Global Group, Inc. and Subsidiaries | | |
Medigap Healthcare Insurance Company LLC | | |
Transaction Accounting Adjustments | | |
Notes | |
Pro Forma Combined | |
ASSETS | |
| | |
| | |
| | |
| |
| |
Current assets: | |
| | | |
| | | |
| | | |
| |
| | |
Cash | |
$ | 4,136,180 | | |
$ | 333,855 | | |
$ | (619,305 | ) | |
(a) (d) (e) | |
$ | 3,850,730 | |
Restricted cash | |
| 484,542 | | |
| - | | |
| - | | |
| |
| 484,542 | |
Accounts receivable | |
| 1,024,831 | | |
| 68,535 | | |
| (68,535 | ) | |
(d) | |
| 1,024,831 | |
Accounts receivable, related parties | |
| 7,131 | | |
| - | | |
| - | | |
| |
| 7,131 | |
Prepaid expense and other current assets | |
| 2,328,817 | | |
| 4,725 | | |
| (2,151,425 | ) | |
(d) (e) | |
| 182,117 | |
Employee retention credit refund receivable | |
| - | | |
| 318,962 | | |
| (318,962 | ) | |
(d) | |
| - | |
Total current assets | |
| 7,981,501 | | |
| 726,077 | | |
| (3,158,227 | ) | |
| |
| 5,549,351 | |
Property and equipment, net | |
| 130,359 | | |
| 20,666 | | |
| - | | |
| |
| 151,025 | |
Right-of-use asset, net | |
| 1,067,734 | | |
| 307,041 | | |
| 12,208 | | |
(c) | |
| 1,386,983 | |
Investment in NSURE, Inc. | |
| 1,350,000 | | |
| - | | |
| - | | |
| |
| 1,350,000 | |
Intangibles, net | |
| 7,078,900 | | |
| - | | |
| 4,665,000 | | |
(c) | |
| 11,743,900 | |
Goodwill | |
| 10,050,277 | | |
| - | | |
| 19,503,996 | | |
(c) | |
| 29,554,273 | |
Other non-current assets | |
| 16,792 | | |
| - | | |
| - | | |
| |
| 16,792 | |
Total assets | |
$ | 27,675,563 | | |
$ | 1,053,784 | | |
$ | 21,022,977 | | |
| |
$ | 49,752,324 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | | |
| | | |
| |
| | |
Current liabilities: | |
| | | |
| | | |
| | | |
| |
| | |
Accounts payable and other accrued liabilities | |
$ | 2,759,160 | | |
$ | 157,266 | | |
$ | (2,303,966 | ) | |
(d) | |
$ | 612,460 | |
Other payables | |
| 81,500 | | |
| - | | |
| - | | |
| |
| 81,500 | |
Current portion of long-term debt | |
| 913,920 | | |
| - | | |
| - | | |
| |
| 913,920 | |
Current portion of leases payable | |
| 276,009 | | |
| 145,311 | | |
| 3,362 | | |
(c) | |
| 424,682 | |
Chargeback reserve | |
| - | | |
| 1,287,461 | | |
| - | | |
| |
| 1,287,461 | |
Earn-out liability, current portion | |
| 3,297,855 | | |
| - | | |
| - | | |
| |
| 3,297,855 | |
Warrant derivative liability | |
| 37,652,808 | | |
| - | | |
| - | | |
| |
| 37,652,808 | |
Total current liabilities | |
| 44,981,252 | | |
| 1,590,038 | | |
| (2,300,604 | ) | |
| |
| 44,270,687 | |
| |
| | | |
| | | |
| | | |
| |
| | |
Loan payables, related parties, less current portion | |
| 353,766 | | |
| - | | |
| - | | |
| |
| 353,766 | |
Long term debt, less current portion | |
| 7,085,325 | | |
| - | | |
| - | | |
| |
| 7,085,325 | |
PPP loan payable | |
| - | | |
| 125,200 | | |
| (125,200 | ) | |
(d) | |
| - | |
Leases payable, less current portion | |
| 805,326 | | |
| 193,478 | | |
| (22,902 | ) | |
(c) | |
| 975,902 | |
Earn-out liability, net of current portion | |
| 516,023 | | |
| - | | |
| - | | |
| |
| 516,023 | |
Total liabilities | |
| 53,741,692 | | |
| 1,908,716 | | |
| (2,448,706 | ) | |
| |
| 53,201,702 | |
| |
| | | |
| | | |
| | | |
| |
| | |
Stockholders’ equity (deficit): | |
| | | |
| | | |
| | | |
| |
| | |
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 9,076 issued and outstanding as of December 31, 2021 | |
| - | | |
| - | | |
| 781 | | |
(e) | |
| 781 | |
Common stock, $0.086 par value; 2,000,000,000 shares authorized and 14,233,038 issued and outstanding as of December 31, 2021 | |
| 940,829 | | |
| - | | |
| 281,816 | | |
(b) (e) | |
| 1,222,645 | |
Stock subscription receivable | |
| (20,000,000 | ) | |
| - | | |
| 20,000,000 | | |
(e) | |
| - | |
Additional paid-in capital | |
| 26,451,187 | | |
| - | | |
| 2,334,154 | | |
(b) (e) | |
| 28,785,341 | |
Accumulated deficit | |
| (33,458,145 | ) | |
| (854,932 | ) | |
| 854,932 | | |
(d) | |
| (33,458,145 | ) |
Total stockholders’ equity (deficit) | |
| (26,066,129 | ) | |
| (854,932 | ) | |
| 23,471,683 | | |
| |
| (3,449,378 | ) |
Total liabilities and stockholders’ equity (deficit) | |
$ | 27,675,563 | | |
$ | 1,053,784 | | |
$ | 21,022,977 | | |
| |
$ | 49,752,324 | |
See
accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Information
Reliance
Global Group, Inc.
Pro
Forma Condensed Combined Consolidated Statement of Operations
December
31, 2021
(Unaudited)
| |
Historical | | |
Pro Forma | |
| |
Reliance Global Group, Inc. and Subsidiaries | | |
Medigap Healthcare Insurance Company LLC | | |
Transaction Accounting Adjustments | | |
Notes | |
Pro Forma Combined | |
REVENUE | |
| | |
| | |
| | |
| |
| |
Commission income | |
$ | 9,710,334 | | |
$ | 5,113,503 | | |
$ | - | | |
| |
$ | 14,823,837 | |
Total revenue | |
| 9,710,334 | | |
| 5,113,503 | | |
| - | | |
| |
| 14,823,837 | |
| |
| | | |
| | | |
| | | |
| |
| | |
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| |
| | |
Commission expense | |
| 2,427,294 | | |
| 594,900 | | |
| - | | |
| |
| 3,022,194 | |
Salaries and wages | |
| 4,672,988 | | |
| 2,253,811 | | |
| - | | |
| |
| 6,926,799 | |
General and administrative expenses | |
| 3,589,221 | | |
| 515,587 | | |
| - | | |
| |
| 4,104,808 | |
Marketing and advertising | |
| 325,838 | | |
| 2,010,691 | | |
| - | | |
| |
| 2,336,529 | |
Depreciation and amortization | |
| 1,607,313 | | |
| 8,573 | | |
| 508,000 | | |
(f) | |
| 2,123,886 | |
Total operating expenses | |
| 12,622,654 | | |
| 5,383,562 | | |
| 508,000 | | |
| |
| 18,514,216 | |
| |
| | | |
| | | |
| | | |
| |
| | |
Loss from operations | |
| (2,912,320 | ) | |
| (270,059 | ) | |
| (508,000 | ) | |
| |
| (3,690,379 | ) |
| |
| | | |
| | | |
| | | |
| |
| | |
Other expense, net | |
| (533,337 | ) | |
| - | | |
| - | | |
| |
| (533,337 | ) |
Recognition and change in derivative liability | |
| (17,652,808 | ) | |
| - | | |
| - | | |
| |
| (17,652,808 | ) |
Interest income (expense), net | |
| - | | |
| (487 | ) | |
| - | | |
| |
| (487 | ) |
Employee retention credit income | |
| - | | |
| 333,437 | | |
| (333,437 | ) | |
(g) | |
| - | |
PPP loan forgiveness | |
| - | | |
| 125,200 | | |
| (125,200 | ) | |
(h) | |
| - | |
| |
| (18,186,145 | ) | |
| 458,150 | | |
| (458,637 | ) | |
| |
| (18,186,632 | ) |
| |
| | | |
| | | |
| | | |
| |
| | |
Net (loss) income | |
$ | (21,098,465 | ) | |
$ | 188,091 | | |
$ | (966,637 | ) | |
| |
$ | (21,877,011 | ) |
| |
| | | |
| | | |
| | | |
| |
| | |
Basic and diluted loss per share | |
$ | (2.09 | ) | |
| | | |
| | | |
| |
$ | (1.64 | ) |
Weighted average number of shares outstanding | |
| 10,097,052 | | |
| | | |
| 3,276,929 | | |
(b) (e) | |
| 13,373,981 | |
See
accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Information
NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Note
1 - Description of Transaction
On
January 10, 2022, Reliance Global Group, Inc. (the “Company”) entered into an agreement (the “APA”) with Medigap
Healthcare Insurance Company, LLC (“Medigap”) pursuant to which the Company purchased all of the assets of Medigap for a
purchase price in the amount of $22,902,201 consisting to payment to Seller of (i) $18,138,750 in cash and (ii) issuing to Seller 606,037
shares of Buyer’s restricted common stock in a transaction exempt from registration under Section 4(a)(2) of the Securities Act
of 1933, as amended. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities
of the parties. The shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50%
of those shares may be sold after the one year anniversary of the date of Closing the APA and the balance of the shares after the second
year anniversary of the date of closing under the APA.
The
purchase consideration for Medigap was financed by the Company through a securities purchase agreement. On December 22, 2021, the Company
entered into a securities purchase agreement (“Purchase Agreement”) with several institutional buyers (the “Buyers”)
for the purchase and sale of (i) warrants (the “Series B Warrants”) to purchase an aggregate of up to 9,779,952 shares of
the Company’s common stock, par value $0.086 per share (the “Common Stock”), (ii) an aggregate of 2,670,892 shares
of Common Stock (the “Common Shares”), and (iii) 9,076 shares (the “Preferred Shares”) of the Company’s
newly-designated Series B convertible preferred stock, par value $0.086 per share (the “Series B Preferred”), with a stated
value of $1,000 per share, initially convertible into an aggregate of 2,219,084 shares of Common Stock at a conversion price of $4.09
per share in a private placement (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred
Shares and the Warrants is approximately $20,000,000, and the Private Placement was closed on January 5, 2022.
Note
2 - Basis of Pro Forma Presentation
The
unaudited pro forma condensed combined balance sheet gives effect to the purchase of Medigap as if it occurred on December 31, 2021.
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2021 gives effect to the acquisition
as if it had occurred on January 1, 2021.
The
historical unaudited pro forma condensed combined balance sheet for the year ended December 31, 2021 combines the Company’s historical
consolidated balance sheet for the year ended December 31, 2021 with the balance sheet of Medigap for the year ended December 31, 2021.
The
historical unaudited pro forma condensed combined statement of operations for the year ended December 31, 2021 combines the Company’s
historical consolidated statement of operations for the year ended December 31, 2021 with the results of Medigap for the year ended December
31, 2021 as derived from the historical statement of operations of Medigap.
The
acquisition was accounted for by the Company as a business combination using the acquisition method of accounting under ASC Topic 805,
Business Combinations. Under the acquisition method of accounting, the purchase price was allocated to the underlying tangible and intangible
assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with any excess purchase price
allocated to goodwill. To date, the Company has estimated a preliminary allocation of the purchase price to the assets acquired and liabilities
assumed in the acquisition, and the final allocation of such purchase price will be determined as further information becomes available.
The final purchase price allocation may differ from that reflected in the following unaudited pro forma condensed combined financial
statements, and these differences may be material.
The
pro forma adjustments reported in these unaudited pro forma condensed combined financial statements are based upon available information
and certain assumptions that the Company’s management believes are reasonable. The unaudited pro forma condensed combined financial
information is presented for informational purposes only and is not intended to represent or be indicative of what the results of operations
or financial condition would have been had the acquisition actually occurred on the dates indicated, nor is it meant to be indicative
of future results of operations or financial condition for any future period or as of any future date. The unaudited pro forma condensed
combined financial information of the Combined Company should be read in conjunction with the audited and unaudited historical financial
statements and related notes of the Company and Medigap.
Assumptions
underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with the unaudited
pro forma condensed combined financial information.
Note
3 – Accounting Policies
The
accounting policies of the Company may vary materially from those of Medigap. During preparation of the unaudited pro forma condensed
combined financial information, the Company has performed a preliminary analysis and is not aware of any material differences, and accordingly,
this unaudited pro forma condensed combined financial information assumes no material differences in accounting policies between the
two companies other than the pro forma reclassifications detailed in Note 5. Following the acquisition date, the Company will conduct
a final review of the accounting policies of Medigap to determine if differences in accounting policies require adjustment or reclassification
to the results of operations of Medigap, or reclassification of assets or liabilities to conform to the accounting policies and classifications
of the Company. As a result of this review, the Company may identify differences that when adjusted or reclassified, could have a material
impact on this unaudited pro forma condensed combined financial information.
Note
4 – Estimated Preliminary Purchase Consideration
The
table below presents the total estimated preliminary purchase consideration:
| |
Amount | |
Cash Consideration | |
$ | 18,138,750 | |
Share Consideration Price at Closing (606,037 common shares) | |
| 4,763,451 | |
Total Purchase Price For Allocation | |
$ | 22,902,201 | |
The
shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50% of those shares may
be sold after the one year anniversary of the date of Closing the APA and the balance of the shares after the second year anniversary
of the date of closing under the APA.
The
estimated preliminary purchase consideration may change materially in connection the work being performed by a third-party valuation
specialist to determine the fair value of the contingent share consideration and determination of the likelihood that the ambassador
agreement can be successfully assigned. The share consideration included in the total estimated preliminary purchase consideration are
estimated using the price of a share of the Company’s common stock at closing.
Note
5 – Reclassification Adjustments
Certain
reclassifications have been made to Medigap’s historical balance sheet to conform the to the Company’s presentation as follows:
Presentation before reclassification | |
Presentation after reclassification | |
December 31, 2021 | |
Shareholder’s deficit | |
Accumulated deficit | |
$ | (854,932 | ) |
Certain
reclassifications have been made to Medigap’s historical statement of operations to conform to the Company’s presentation
as follows:
Presentation before reclassification | |
Presentation after reclassification | |
For the Year Ended December 31, 2021 | |
Compensation expense | |
Salaries and wages | |
$ | 2,253,811 | |
Note
6 – Transaction Accounting Adjustments
a) |
Represents
the total cash consideration paid at closing for the acquisition Medigap of $18,138,750. |
|
|
b) |
Represents share consideration
paid at closing. The Company issued 606,037 shares of common stock for the acquisition of Medigap with a fair value of $4,763,451
determined using the share price on the acquisition date of $7.86 (606,037 shares of common stock issued with a par value of $.0001).
The shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50% of those shares
may be sold after the one year anniversary of the date of Closing the APA and the balance of the shares after the second year anniversary
of the date of closing under the APA. |
|
|
c) |
Represents the estimate
of goodwill in the amount of $19,503,996, acquired intangible assets in the amount of $4,665,000, the increase of the right-of-use
asset by $12,208, and the decrease of the lease liability by $19,540, resulting from the acquisition of Medigap determined using
the purchase consideration of $22,902,201 (refer to Note 4), net of assets and liabilities assumed of a net liability in the amount
of $1,259,463. |
|
|
d) |
The historical accumulated
deficit of Medigap of $854,932, and all assets and liabilities not acquired by the Company, were eliminated in the unaudited pro
forma condensed combined balance sheet at December 31, 2021. |
|
|
e) |
On December 22, 2021, the
Company entered into a securities purchase agreement (“Purchase Agreement”) with several institutional buyers (the “Buyers”)
for the purchase and sale of (i) warrants (the “Series B Warrants”) to purchase an aggregate of up to 9,779,952 shares
of the Company’s common stock, par value $0.086 per share (the “Common Stock”), (ii) an aggregate of 2,670,892
shares of Common Stock (the “Common Shares”), and (iii) 9,076 shares (the “Preferred Shares”) of the Company’s
newly-designated Series B convertible preferred stock, par value $0.086 per share (the “Series B Preferred”), with a
stated value of $1,000 per share, initially convertible into an aggregate of 2,219,084 shares of Common Stock at a conversion price
of $4.09 per share in a private placement (the “Private Placement”). The aggregate purchase price for the Common Shares,
the Preferred Shares and the Warrants is approximately $20,000,000, and the Private Placement was closed on January 5, 2022. Total
cash received, net of transaction costs of $2,146,700, was $17,583,300. |
|
|
f) |
Represents the amortization
of the intangible assets recorded in the unaudited pro forma condensed combined statement of operations for the year ended December
31, 2021. |
|
|
g) |
Represents an adjustment
for the year ended December 31, 2021 to eliminate the government grant income associated with the employee retention credit that
was enacted under the CARES Act. The government grant income of $333,437 will be retained by the Seller. |
|
|
h) |
Represents an adjustment
to eliminate the debt forgiveness income associated with loan proceeds under the Paycheck Protection Program, which was established
under the congressionally approved Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). During the year
ended December 31, 2021, Medigap received notification from the U.S. Small Business Administration that the entire amount of the
loan was forgiven. |
APPENDIX
C